Articles
 News Headlines
 Journal Headlines

  Home
  Archives
  Site Map
   
May 9, 2008
 
About AIDScience
Contact Us
——
NeuroAIDS
 
 
 
 

Vol. 3, No. 8, 2 May 2003
Other Issues:



From Science:
Hypermutation of HIV-1 DNA in the absence of the Vif protein
Vif-negative HIV's propagation in host cells is blocked by the cytidine deaminase CEM 15. Full-text article.

— By Allan J. Hance et al. 
[About AIDScience articles] [See recent AIDScience articles]
 
Hot News:
Vpr mutation associated with long-term nonprogressive HIV infection
The (H[F/S]RIG)2 domain of viral protein R (Vpr) induces apoptosis and may contribute to HIV-induced T cell depletion. Journal of Clinical Investigation 111(10), 1547, 15 May 2003.
 
From Medscape: The 12th Annual Canadian Conference on HIV/AIDS Research
Highlights of the meeting that took place 10-13 April, 2003, in Halifax, Nova Scotia, Canada. (Medscape requires one-time free registration)
 
Report: large gap between HIV prevention needs and current efforts
Fewer than one in five people at risk of HIV infection today have access to prevention programs, and annual global spending on prevention falls $3.8 billion short of what will be needed by 2005, according to a new report.
 
Tracing the origin and history of the HIV-2 epidemic
Evidence for a zoonotic transfer of HIV-2 during the first half of the 20th century and an epidemic initiation in Guinea-Bissau that coincides with the independence war (1963-1974). Proc. Natl. Acad. Sci. USA, published online before print May 12, 2003.
 
Is it sex or poor medical practices?
BBC News reports contaminated needles are the primary mode of HIV transmission among children in South Africa, according to a study published in the British Journal of Obstetrics and Gynaecology 110(5), 450, May 2003.
 
Trials of AIDS vaccine to start in Switzerland and the U.K.
Clinical trials of a new vaccine against HIV, organized by EuroVacc, start in Switzerland and the U.K. in June to test DNA-C, developed by Professor Hans Wolf of the University of Regensburg, Germany, and its booster, NYVAC, developed by the French pharmaceutical company Aventis. British Medical Journal 326, 952, 3 May 2003.
 
Trials of AIDS vaccine to start in India
Phase I trials will begin later this year or early next year. The International AIDS Vaccine Initiative has been working closely with the Indian Council of Medical Research and the National AIDS Control Organisation since December 2000 to develop and evaluate AIDS vaccines in India. British Medical Journal 326, 952, 3 May 2003.
 

ADODB.Connection error '800a0e7a'

Provider cannot be found. It may not be properly installed.

/Issues/Issue050.asp, line 100

Latest News Headlines
[What is this?]